|
2025
|
P/S
|
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of... |
|
|
Invention
|
Polynucleotide purification with monolith columns.
Described herein are methods of purifying pol... |
|
|
Invention
|
Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) w... |
|
|
Invention
|
Risk evaluation and management strategy involving patient follow-ups relating to the use or disco... |
|
|
Invention
|
Treatment of mayo stage iiib light chain amyloidosis. The disclosure is directed to methods of de... |
|
|
Invention
|
Methods for treating lymphoma.
Compositions and methods for treating lymphoma, in particular. T-... |
|
|
Invention
|
Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan). e.ge.g., suc... |
|
|
Invention
|
Methods for treatment of refractory generalized myasthenia gravis.
The disclosure provides metho... |
|
|
Invention
|
High concentration anti-c5 antibody formulations.
The present disclosure relates to stable aqueo... |
|
|
Invention
|
Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturna... |
|
|
Invention
|
Anti-c5 antibodies having improved pharmacokinetics.
The disclosure provides antibodies that are... |
|
|
Invention
|
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinu... |
|
|
Invention
|
Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof.
The... |
|
2024
|
Invention
|
Antidotes to factor xa inhibitors.
The present disclosure relates to antidotes to anticoagulants... |
|
|
Invention
|
Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or pr... |
|
|
Invention
|
Lyophilized formulations for factor xa antidote.
The present disclosure relates to solutions and... |
|
|
Invention
|
Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis.
... |
|
|
Invention
|
Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same.
The p... |
|
|
Invention
|
Treatment of intracranial hemorrhage. The present disclosure relates to compositions and methods ... |
|
|
Invention
|
Methods for treating lysosomal acid lipase deficiency in patients.
The present invention provide... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of complement-mediated hematological diseases and d... |
|
|
Invention
|
Alkaline phosphatase polypeptides and methods of use thereof.
Featured are pharmaceutical compos... |
|
|
Invention
|
Immunosuppressive therapy to mitigate anti-soluble alkaline phosphatase immune response. The disc... |
|
|
Invention
|
Methods for the synthesis of complement factor d inhibitors and intermediates thereof. The presen... |
|
|
Invention
|
Methods and compositions for treating complement-associated disorders.
The present disclosure re... |
|
|
Invention
|
Use of biomarkers for the identification and treatment of complement-mediated disorders. A method... |
|
|
Invention
|
Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles.... |
|
|
Invention
|
High throughput fab antibody fragment generation and ranking. Methods and assays are provided for... |
|
|
Invention
|
Pediatric dosage and administration of anti-c5 antibodies for treatment of complement disorders. ... |
|
|
Invention
|
Systems and methods for monitoring quality of life (qol) features in pnh patients treated with co... |
|
|
P/S
|
Pharmaceutical preparations and substances. |
|
|
P/S
|
Pharmaceutical preparations and substances for the treatment of complement-medicated diseases and... |
|
|
Invention
|
Treating muscle weakness with alkaline phosphatases. ALPL ALPL gene. |
|
|
Invention
|
Systems and methods for identifying atypical hemolytic uremic syndrome (ahus) patients using clin... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of complement-mediated diseases and disorders |
|
|
Invention
|
Formulations of danicopan and methods of use thereof. This present disclosure features solid disp... |
|
2023
|
Invention
|
Compositions and methods for increasing the serum half-life of a therapeutic agent targeting comp... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of enzyme
deficiencies; pharmaceutical preparation... |
|
|
Invention
|
High sensitivity biotinylated peptide binding elisa assay.
Immunoglobulin light Chain “AL” amylo... |
|
|
Invention
|
Compositions and methods for preventing and treating cytokine release syndrome.
Compositions and... |
|
|
Invention
|
Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wi... |
|
2022
|
P/S
|
Pharmaceutical preparations for the treatment of hematological, nephrological, autoimmune, immuno... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of
hematological, nephrological, autoimmune, immun... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of complement-mediated hematological, nephrological... |
|
|
Invention
|
Methods for the synthesis of complement factor d inhibitors and intermediates thereof.
The prese... |
|
|
Invention
|
Methods for the synthesis of complement factor d inhibitors.
The present disclosure provides met... |
|
|
Invention
|
Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephro... |
|
|
Invention
|
Methods of treating copper metabolism-associated diseases or disorders.
Disclosed are methods of... |
|
|
Invention
|
Assay methods for screening inhibitors of sickle cell disease, ß-thalassemia, or sickle cell ß-th... |
|
|
Invention
|
Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathw... |
|
|
Invention
|
Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway... |
|
|
Invention
|
Methods of treating copper metabolism-associated diseases or disorders.
This disclosure relates ... |
|
|
Invention
|
Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis.
Provided are... |
|
|
Invention
|
Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm).
Provided are ... |
|
|
Invention
|
Methods for detecting cm-tma biomarkers.
Provided are agents and methods for the detection of co... |
|
|
Invention
|
Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related... |
|
|
Invention
|
Kidney active fusion proteins and methods of treatment using the same.
Described herein are fusi... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of inflammatory diseases and disorders, autoimmune ... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of autoimmune diseases and disorders, protein aggre... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of
inflammatory diseases and disorders, autoimmune... |
|
2021
|
P/S
|
Pharmaceutical preparations for the treatment of hematological, autoimmune, dermatological, neuro... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of hematological, autoimmune, dermatological, immun... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of hematological, autoimmune, and immunological dis... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of
hematological, autoimmune, dermatological, neur... |
|
|
P/S
|
Pharmaceutical preparations for use in oncology and
hematology; pharmaceutical preparations for ... |
|
|
P/S
|
Pharmaceutical preparations for treatment of metabolic disorders, namely, copper metabolism disor... |
|
|
P/S
|
Pharmaceutical preparations for treatment of metabolic disorders. |
|
|
P/S
|
Pharmaceutical preparations. |
|
|
P/S
|
Pharmaceutical preparations for treatment of metabolic
disorders. |
|
2020
|
P/S
|
Administration of a program to promote community service; charitable services, namely, management... |
|
2019
|
Invention
|
Complement factor h and fc binding domain fusion proteins.
Described herein are fusion proteins ... |
